The reasons for triple therapy in stable COPD patients in Japanese clinical practice.

Miyazaki, Masaki; Nakamura, Hidetoshi; Takahashi, Saeko; Chubachi, Shotaro; Sasaki, Mamoru; Haraguchi, Mizuha; Terai, Hideki; Ishii, Makoto; Fukunaga, Koichi; Tasaka, Sadatomo; Soejima, Kenzo; Asano, Koichiro; Betsuyaku, Tomoko

doi:10.2147/COPD.S79864

Record: found
Abstract: found
Article: not found

The reasons for triple therapy in stable COPD patients in Japanese clinical practice.

Author(s): Masaki Miyazaki, Hidetoshi Nakamura, Saeko Takahashi, Shotaro Chubachi, Mamoru Sasaki, Mizuha Haraguchi, Hideki Terai, Makoto Ishii, Koichi Fukunaga, Sadatomo Tasaka, Kenzo Soejima, Koichiro Asano, Tomoko Betsuyaku

Publication date: 2015

Journal: International Journal of Chronic Obstructive Pulmonary Disease

Publisher: Informa UK Ltd.

Keywords: inhaled corticosteroids, long-acting β2 agonists, long-acting muscarinic antagonists, triple therapy, chronic obstructive pulmonary disease

Read this article at

ScienceOpenPublisher PMC

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Triple combination therapy involving long-acting muscarinic antagonists long-acting β2 agonists, and inhaled corticosteroids has recently become an option for maintenance treatment of COPD. Some add-on clinical trials have reported the benefits of these combinations. However, the process to step up to triple therapy varies for individual cases.